Quantinno Capital Management LP Has $660,000 Holdings in Masimo Co. (NASDAQ:MASI)

Quantinno Capital Management LP raised its stake in Masimo Co. (NASDAQ:MASI - Free Report) by 89.1% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 3,990 shares of the medical equipment provider's stock after purchasing an additional 1,880 shares during the quarter. Quantinno Capital Management LP's holdings in Masimo were worth $660,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors also recently modified their holdings of MASI. FMR LLC boosted its holdings in Masimo by 19.8% in the fourth quarter. FMR LLC now owns 8,097,454 shares of the medical equipment provider's stock valued at $1,338,509,000 after purchasing an additional 1,340,836 shares during the last quarter. Vanguard Group Inc. lifted its position in shares of Masimo by 1.5% in the 4th quarter. Vanguard Group Inc. now owns 4,586,702 shares of the medical equipment provider's stock worth $758,182,000 after buying an additional 66,215 shares during the last quarter. Capital Research Global Investors boosted its stake in Masimo by 80.5% in the fourth quarter. Capital Research Global Investors now owns 2,454,975 shares of the medical equipment provider's stock valued at $405,807,000 after acquiring an additional 1,094,647 shares during the period. Massachusetts Financial Services Co. MA boosted its position in Masimo by 119.0% during the 4th quarter. Massachusetts Financial Services Co. MA now owns 1,735,167 shares of the medical equipment provider's stock valued at $286,823,000 after purchasing an additional 943,001 shares during the period. Finally, T. Rowe Price Investment Management Inc. grew its position in shares of Masimo by 8.9% during the fourth quarter. T. Rowe Price Investment Management Inc. now owns 1,662,376 shares of the medical equipment provider's stock worth $274,791,000 after acquiring an additional 135,888 shares during the last quarter. Institutional investors and hedge funds own 85.96% of the company's stock.

Insiders Place Their Bets

In related news, COO Bilal Muhsin sold 10,000 shares of the stock in a transaction dated Monday, May 12th. The stock was sold at an average price of $163.28, for a total value of $1,632,800.00. Following the completion of the sale, the chief operating officer now directly owns 24,172 shares of the company's stock, valued at approximately $3,946,804.16. This represents a 29.26% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Craig B. Reynolds sold 2,053 shares of the business's stock in a transaction that occurred on Friday, March 14th. The shares were sold at an average price of $166.13, for a total transaction of $341,064.89. Following the transaction, the director now directly owns 16,581 shares in the company, valued at $2,754,601.53. The trade was a 11.02% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 42,053 shares of company stock worth $6,998,565. 9.70% of the stock is owned by insiders.

Analysts Set New Price Targets

MASI has been the subject of several analyst reports. BTIG Research set a $193.00 price objective on Masimo and gave the stock a "buy" rating in a research report on Wednesday, May 7th. Wells Fargo & Company reduced their price target on Masimo from $205.00 to $190.00 and set an "overweight" rating for the company in a research report on Wednesday, May 7th. Piper Sandler reissued an "overweight" rating and issued a $200.00 price target (down previously from $215.00) on shares of Masimo in a research note on Wednesday, May 7th. Needham & Company LLC restated a "hold" rating on shares of Masimo in a research note on Thursday, April 10th. Finally, Raymond James decreased their target price on shares of Masimo from $204.00 to $185.00 and set an "outperform" rating for the company in a research report on Wednesday, May 7th. One equities research analyst has rated the stock with a hold rating and five have issued a buy rating to the company. Based on data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and a consensus target price of $191.60.

Masimo Price Performance

Shares of MASI traded up $2.72 during midday trading on Friday, reaching $159.69. The stock had a trading volume of 124,811 shares, compared to its average volume of 648,638. The company has a debt-to-equity ratio of 0.50, a current ratio of 2.01 and a quick ratio of 1.11. The company has a market capitalization of $8.66 billion, a P/E ratio of 110.14 and a beta of 1.23. The firm's 50 day moving average price is $157.30 and its 200-day moving average price is $167.14. Masimo Co. has a 52 week low of $101.61 and a 52 week high of $194.88.

Masimo (NASDAQ:MASI - Get Free Report) last issued its quarterly earnings results on Tuesday, May 6th. The medical equipment provider reported $1.36 earnings per share for the quarter, beating analysts' consensus estimates of $1.24 by $0.12. The company had revenue of $372.00 million during the quarter, compared to the consensus estimate of $367.79 million. Masimo had a net margin of 3.85% and a return on equity of 14.98%. Masimo's revenue was down 24.5% on a year-over-year basis. During the same period in the prior year, the company earned $0.77 EPS. On average, analysts forecast that Masimo Co. will post 4.1 earnings per share for the current fiscal year.

Masimo Company Profile

Masimo Corporation develops, manufactures, and markets various patient monitoring technologies, and automation and connectivity solutions worldwide. The company offers masimo signal extraction technology (SET) pulse oximetry with measure-through motion and low perfusion pulse oximetry monitoring to address the primary limitations of conventional pulse oximetry; Masimo rainbow SET platform, including rainbow SET Pulse CO-Oximetry products that allows noninvasive monitoring of carboxyhemoglobin, methemoglobin, hemoglobin concentration, fractional arterial oxygen saturation, oxygen content, pleth variability index, rainbow pleth variability index, respiration rate from the pleth, and oxygen reserve index, as well as acoustic respiration monitoring, SedLine brain function monitoring, NomoLine capnography and gas monitoring, and regional oximetry.